Research Analysts Offer Predictions for AVBP FY2025 Earnings

ArriVent BioPharma, Inc. (NASDAQ:AVBP) – Lifesci Capital dropped their FY2025 EPS estimates for shares of ArriVent BioPharma in a report released on Monday, June 23rd. Lifesci Capital analyst S. Slutsky now expects that the company will post earnings of ($3.99) per share for the year, down from their prior forecast of ($3.97). The consensus estimate for ArriVent BioPharma’s current full-year earnings is ($2.74) per share. Lifesci Capital also issued estimates for ArriVent BioPharma’s FY2026 earnings at ($4.03) EPS.

ArriVent BioPharma (NASDAQ:AVBP) last posted its earnings results on Monday, May 12th. The company reported ($1.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($1.24).

A number of other research firms also recently commented on AVBP. Oppenheimer restated an “outperform” rating and set a $44.00 price target (up from $39.00) on shares of ArriVent BioPharma in a research report on Tuesday. Guggenheim restated a “buy” rating and set a $45.00 price target on shares of ArriVent BioPharma in a research report on Tuesday. HC Wainwright boosted their price target on shares of ArriVent BioPharma from $39.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, May 14th. Jones Trading started coverage on shares of ArriVent BioPharma in a research report on Tuesday, May 20th. They set a “buy” rating and a $40.00 price target on the stock. Finally, Wall Street Zen downgraded shares of ArriVent BioPharma from a “hold” rating to a “strong sell” rating in a research report on Thursday, May 22nd. One research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $40.00.

ArriVent BioPharma Stock Up 0.0%

ArriVent BioPharma stock opened at $22.81 on Thursday. ArriVent BioPharma has a 52-week low of $15.47 and a 52-week high of $36.37. The firm has a market capitalization of $780.33 million, a price-to-earnings ratio of -6.05 and a beta of 1.26. The firm has a 50-day moving average price of $21.56 and a two-hundred day moving average price of $23.03.

Institutional Trading of ArriVent BioPharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Jane Street Group LLC bought a new position in shares of ArriVent BioPharma in the first quarter valued at $189,000. Woodline Partners LP grew its holdings in shares of ArriVent BioPharma by 0.4% in the 1st quarter. Woodline Partners LP now owns 146,373 shares of the company’s stock worth $2,706,000 after acquiring an additional 576 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of ArriVent BioPharma during the first quarter worth $266,000. Infinitum Asset Management LLC lifted its holdings in shares of ArriVent BioPharma by 25.7% during the first quarter. Infinitum Asset Management LLC now owns 2,066,238 shares of the company’s stock valued at $38,205,000 after purchasing an additional 422,315 shares during the last quarter. Finally, Wellington Management Group LLP lifted its holdings in shares of ArriVent BioPharma by 46.3% during the first quarter. Wellington Management Group LLP now owns 61,348 shares of the company’s stock valued at $1,134,000 after purchasing an additional 19,427 shares during the last quarter. 9.48% of the stock is owned by institutional investors and hedge funds.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.